<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "8: effectively discover", fill: "#7df9ff"},
{source: "8: effectively discover", target: "8: regulatory", fill: "#7df9ff"},
{source: "8: regulatory", target: "8: products as well as", fill: "#7df9ff"},
{source: "8: products as well as", target: "8: effectively commercialize market", fill: "#7df9ff"},
{source: "8: effectively commercialize market", target: "8: promote approved products", fill: "#7df9ff"},
{source: "8: promote approved products", target: "8: effectiveness safety", fill: "#7df9ff"},
{source: "8: effectiveness safety", target: "8: prospective customers", fill: "#7df9ff"},
{source: "8: prospective customers", target: "8: medical professionals", fill: "#7df9ff"},
{source: "8: effectively discover", target: "9: competitors", fill: "#a8516e"},
{source: "9: competitors", target: "15: eye care products", fill: "#df00ff"},
{source: "15: eye care products", target: "15: manufacture", fill: "#df00ff"},
{source: "15: manufacture", target: "15: effectively market", fill: "#df00ff"},
{source: "15: effectively market", target: "15: eye care professionals", fill: "#df00ff"},
{source: "15: eye care professionals", target: "15: current products", fill: "#df00ff"},
{source: "15: current products", target: "15: new products", fill: "#df00ff"},
{source: "15: new products", target: "15: may introduce", fill: "#df00ff"},
{source: "15: eye care products", target: "21: Dysport ", fill: "#c04000"},
{source: "21: Dysport ", target: "21: neuromodulator", fill: "#c04000"},
{source: "21: neuromodulator", target: "21: therapeutic", fill: "#c04000"},
{source: "21: therapeutic", target: "21: indications", fill: "#c04000"},
{source: "21: Dysport ", target: "22: While Beaufour Ipsen ", fill: "#5d8aa8"},
{source: "22: While Beaufour Ipsen ", target: "22: previously", fill: "#5d8aa8"},
{source: "22: previously", target: "22: indication", fill: "#5d8aa8"},
{source: "22: indication", target: "22: United States ", fill: "#5d8aa8"},
{source: "22: United States ", target: "22: licensed rights from", fill: "#5d8aa8"},
{source: "22: licensed rights from", target: "22: connection", fill: "#5d8aa8"},
{source: "22: connection", target: "22: acquisition", fill: "#5d8aa8"},
{source: "22: While Beaufour Ipsen ", target: "24: Beaufour Ipsen ", fill: "#1c39bb"},
{source: "24: Beaufour Ipsen ", target: "24: Dysport in Europe ", fill: "#1c39bb"},
{source: "24: Dysport in Europe ", target: "24: commercialization", fill: "#1c39bb"},
{source: "24: Beaufour Ipsen ", target: "30: Merz Pharmaceuticals ", fill: "#253529"},
{source: "30: Merz Pharmaceuticals ", target: "30: authorities", fill: "#253529"},
{source: "30: authorities", target: "30: botulinum toxin", fill: "#253529"},
{source: "30: botulinum toxin", target: "30: Phase III ", fill: "#253529"},
{source: "30: Phase III ", target: "30: clinical trials", fill: "#253529"},
{source: "30: Merz Pharmaceuticals ", target: "40: cannot assure", fill: "#0cc"},
{source: "40: cannot assure", target: "40: Juvederm in the United States ", fill: "#0cc"},
{source: "40: Juvederm in the United States ", target: "40: will offer equivalent", fill: "#0cc"},
{source: "40: will offer equivalent", target: "40: greater facial aesthetic benefits", fill: "#0cc"},
{source: "40: greater facial aesthetic benefits", target: "40: competitive", fill: "#0cc"},
{source: "40: competitive", target: "40: gain acceptance", fill: "#0cc"},
{source: "40: cannot assure", target: "102: agreements will", fill: "#1c352d"},
{source: "102: agreements will", target: "102: every instance", fill: "#1c352d"},
{source: "102: every instance", target: "102: adequate remedies", fill: "#1c352d"},
{source: "102: agreements will", target: "134: product liability", fill: "#b31b1b"},
{source: "134: product liability", target: "134: product recalls", fill: "#b31b1b"},
{source: "134: product recalls", target: "134: corrections", fill: "#b31b1b"},
{source: "134: product liability", target: "START_HERE", fill: "#b31b1b"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Home Improvement Retail</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cis-regulatory_element">Cis-regulatory element</a></td>
      <td>Cis-regulatory elements (CREs) or Cis-regulatory modules (CRMs) are regions of non-coding DNA which regulate the transcription of neighboring genes. CREs are vital components of genetic regulatory networks, which in turn control morphogenesis, the development of anatomy, and other aspects of embryonic development, studied in evolutionary developmental biology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_law">Regulatory law</a></td>
      <td>Regulatory law refers to secondary legislation, including regulations, promulgated by an executive branch agency under a delegation from a legislature. It contrasts with statutory law promulgated by the legislative branch, and common law or case law promulgated by the judicial branch.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_royale">Manufacture royale</a></td>
      <td>Manufacture Royale is a Swiss luxury watch brand. Founded in the eighteenth century, the brand was revived in 2010.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_geographical_indications_in_India">List of geographical indications in India</a></td>
      <td>A geographical indication (GI) is a name or sign used on certain products which corresponds to a specific geographical location or origin (e.g., a town, region, or country). India, as a member of the World Trade Organization (WTO), enacted the Geographical Indications of Goods (Registration and Protection) Act, 1999 has come into force with effect from 15 September 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Empirical_evidence">Empirical evidence</a></td>
      <td>Empirical evidence for a proposition is evidence, i.e. what supports or counters this proposition, that is constituted by or accessible to sense experience or experimental procedure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Geographical_indications_and_traditional_specialities_in_the_European_Union">Geographical indications and traditional specialities in the European Union</a></td>
      <td>Three European Union schemes of geographical indications and traditional specialties, known as protected designation of origin (PDO), protected geographical indication (PGI), and traditional specialities guaranteed (TSG), promote and protect names of agricultural products and foodstuffs. Products registered under one of the three schemes may be marked with the logo for that scheme to help identify those products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Geographical_Indications_of_Goods_(Registration_and_Protection)_Act,_1999">Geographical Indications of Goods (Registration and Protection) Act, 1999</a></td>
      <td>The Geographical Indications of Goods (Registration and Protection) Act, 1999 (GI Act) is a sui generis Act of the Parliament of India for protection of geographical indications in India. India, as a member of the World Trade Organization (WTO), enacted the Act to comply with the Agreement on Trade-Related Aspects of Intellectual Property Rights.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Marine_Corps">United States Marine Corps</a></td>
      <td>The United States Marine Corps (USMC), also referred to as the United States Marines, is the maritime land force service branch of the United States Armed Forces responsible for conducting expeditionary and amphibious operations through combined arms, implementing its own infantry, artillery, aerial, and special operations forces. The U.S. Marine Corps is one of the eight uniformed services of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mergers_and_acquisitions">Mergers and acquisitions</a></td>
      <td>In corporate finance, mergers and acquisitions (M&amp;A) are transactions in which the ownership of companies, other business organizations, or their operating units are transferred or consolidated with other entities. As an aspect of strategic management, M&amp;A can allow enterprises to grow or downsize, and change the nature of their business or competitive position.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Target_acquisition">Target acquisition</a></td>
      <td>Target acquisition is the detection and identification of the location of a target in sufficient detail to permit the effective employment of lethal and non-lethal means. The term is used for a broad area of applications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Resource_acquisition_is_initialization">Resource acquisition is initialization</a></td>
      <td>Resource acquisition is initialization (RAII) is a programming idiom used in several object-oriented, statically-typed programming languages to describe a particular language behavior.  In RAII, holding a resource is a class invariant, and is tied to object lifetime.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Right_to_Fair_Compensation_and_Transparency_in_Land_Acquisition,_Rehabilitation_and_Resettlement_Act,_2013">Right to Fair Compensation and Transparency in Land Acquisition, Rehabilitation and Resettlement Act, 2013</a></td>
      <td>The Right to Fair Compensation and Transparency in Land Acquisition, Rehabilitation and Resettlement Act, 2013 (also Land Acquisition Act, 2013 or LARR Act or RFCTLARR Act) is an Act of Indian Parliament that regulates land acquisition and lays down the procedure and rules for granting compensation, rehabilitation and resettlement to the affected persons in India. The Act has provisions to provide fair compensation to those whose land is taken away, brings transparency to the process of acquisition of land to set up factories or buildings, infrastructural projects and assures rehabilitation of those affected.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Certificate_authority">Certificate authority</a></td>
      <td>In cryptography, a certificate authority or certification authority (CA) is an entity that stores, signs, and issues digital certificates.  A digital certificate certifies the ownership of a public key by the named subject of the certificate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Alisher_Usmanov">Alisher Usmanov</a></td>
      <td>Alisher Burkhanovich Usmanov (Russian: Алишер Бурханович Усманов; born 9 September 1953) is an Uzbek-born Russian businessman and oligarch. By 2022, Usmanov had an estimated net worth of $19.5 billion and was among the world's 100 wealthiest people.Usmanov made his wealth after the collapse of the Soviet Union, through metal and mining operations, and investments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hardware_random_number_generator">Hardware random number generator</a></td>
      <td>In computing, a hardware random number generator (HRNG) or true random number generator (TRNG) is a device that generates random numbers from a physical process, rather than by means of an algorithm.  Such devices are often based on microscopic phenomena that generate low-level, statistically random "noise" signals, such as thermal noise, the photoelectric effect, involving a beam splitter, and other quantum phenomena.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tourism_in_Abkhazia">Tourism in Abkhazia</a></td>
      <td>Tourism in Abkhazia is possible under Georgian law for foreigners entering the occupied territory from Georgia, although Georgia cannot assure the safety inside disputed territory.\nHowever, the Abkazian beaches on the Black Sea continue to be accessible for tourists coming from the Russian side of the Abkhazia–Russia border which is not under Georgian control.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Synchroscope">Synchroscope</a></td>
      <td>In AC electrical power systems, a synchroscope is a device that indicates the degree to which two systems (generators or power networks) are synchronized with each other.For two electrical systems to be synchronized, both systems must operate at the same frequency, and the phase angle between the systems must be zero (and two polyphase systems must have the same phase sequence). Synchroscopes measure and display the frequency difference and phase angle between two power systems.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/What's_Your_Raashee?">What's Your Raashee?</a></td>
      <td>What's Your Raashee? (lit. 'What's Your Zodiac Sign?') is a 2009 Indian Hindi-language romantic comedy film written and directed by Ashutosh Gowariker.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_license">Medical license</a></td>
      <td>A medical license is an occupational license that permits a person to legally practice medicine. In most countries, a person must have a medical license bestowed either by a specified government-approved professional association or a government agency before he or she can practice medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_liability">Product liability</a></td>
      <td>Product liability is the area of law in which manufacturers, distributors, suppliers, retailers, and others who make products available to the public are held responsible for the injuries those products cause. Although the word "product" has broad connotations, product liability as an area of law is traditionally limited to products in the form of tangible personal property.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tort_reform">Tort reform</a></td>
      <td>Tort reform refers to changes in the civil justice system in common law countries that aim to reduce the ability of plaintiffs to bring tort litigation (particularly actions for negligence) or to reduce damages they can receive. Such changes are generally justified under the grounds that litigation is an inefficient means to compensate plaintiffs; that tort law permits frivolous or otherwise undesirable litigation to crowd the court system; or that the fear of litigation can serve to curtail innovation, raise the cost of consumer goods or insurance premiums for suppliers of services (e.g.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ALLERGAN INC      Item 1A Risk Factors             We operate in a rapidly changing <font color="blue">environment</font> that involves a number of     risks</td>
    </tr>
    <tr>
      <td>The following discussion <font color="blue">highlights</font> some of these risks and others     are <font color="blue">discussed elsewhere</font> in this report</td>
    </tr>
    <tr>
      <td>These and other <font color="blue">risks could</font>                                         16       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font><font color="blue">materially</font>  and  <font color="blue">adversely</font>  affect  our business, <font color="blue">financial condition</font>,     prospects, operating results or <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">following risk factors</font> are     not  an <font color="blue">exhaustive list</font> of the <font color="blue">risks <font color="blue">associated with</font></font> our business</td>
    </tr>
    <tr>
      <td>New     factors  may  emerge  or changes to these <font color="blue">risks could</font> occur that could     <font color="blue">materially</font> affect our business</td>
    </tr>
    <tr>
      <td>We operate in a <font color="blue">highly <font color="blue">competitive</font></font> business</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">pharmaceutical</font> industry</font> is <font color="blue">highly <font color="blue">competitive</font></font> and requires an     ongoing, extensive search for <font color="blue">technological innovation</font></td>
    </tr>
    <tr>
      <td>It also requires,     among other things, the ability to <font color="blue"><font color="blue">effective</font>ly discover</font>, develop, test and     obtain  <font color="blue">regulatory</font>  approvals  for products, as well as the ability to     <font color="blue">effective</font>ly <font color="blue">commercialize</font>, market and <font color="blue">promote approved products</font>, including     communicating the <font color="blue">effective</font>ness, safety and value of products to actual and     <font color="blue">prospective customers</font> and <font color="blue">medical professionals</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue"><font color="blue">competitor</font>s</font> have greater resources than we have</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>enables them, among other things, to make <font color="blue">greater research</font> and <font color="blue">development</font>     <font color="blue">investments</font> and spread their research and <font color="blue">development</font> costs, as well as     their  marketing and promotion costs, over a <font color="blue">broader revenue base</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue"><font color="blue">competitor</font>s</font>  may  also have more experience and expertise in obtaining     marketing  <font color="blue">approvals from</font> the FDA and other <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>In     addition to product <font color="blue">development</font>, testing, approval and promotion, other     <font color="blue">competitive</font>  factors  in  the <font color="blue"><font color="blue">pharmaceutical</font> industry</font> include industry     consolidation, product quality and price, product technology, reputation,     <font color="blue">customer service</font> and access to technical information</td>
    </tr>
    <tr>
      <td>It is possible that <font color="blue">development</font>s by our <font color="blue"><font color="blue">competitor</font>s</font> could make our     products or <font color="blue">technologies</font> less <font color="blue">competitive</font> or obsolete</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future growth</font>     depends,  in  part,  on our ability to develop <font color="blue">products which</font> are more     <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>For instance, for our <font color="blue">eye care products</font> to be successful, we must     be able to <font color="blue">manufacture</font> and <font color="blue">effective</font>ly market those products and persuade a     sufficient number of <font color="blue">eye care professionals</font> to use or continue to use our     <font color="blue">current products</font> and the <font color="blue">new products</font> we <font color="blue">may introduce</font></td>
    </tr>
    <tr>
      <td>Glaucoma must be     <font color="blue">treated over</font> an <font color="blue">extended period</font> and <font color="blue">doctors may</font> be reluctant to switch a     patient to a <font color="blue">new treatment</font> if the patient’s current treatment for glaucoma     remains <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>Sales of our <font color="blue">existing products</font> may decline rapidly if a     new product is introduced by one of our <font color="blue"><font color="blue">competitor</font>s</font> or if we announce a new     product that, in either case, <font color="blue">represents</font> a substantial <font color="blue">improvement</font> over our     <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>Similarly, if we fail to make sufficient <font color="blue">investments</font> in     research and <font color="blue">development</font> programs, our current and planned <font color="blue">products could</font> be     surpassed  by  more  <font color="blue">effective</font>  or  <font color="blue">advanced products</font> developed by our     <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Until <font color="blue">December </font></font>2000, Botox^® was the <font color="blue">only <font color="blue">neuromodulator</font> <font color="blue">approved by</font></font>     the FDA At that time, the FDA approved Myobloc^®, a <font color="blue">neuromodulator</font> formerly     marketed by <font color="blue">Elan Pharmaceuticals </font>and now marketed by Solstice Neurosciences,     Inc</td>
    </tr>
    <tr>
      <td>is  seeking FDA approval of its Dysport^®     <font color="blue">neuromodulator</font>  for  certain  <font color="blue">therapeutic</font>  <font color="blue"><font color="blue">indication</font>s</font> and approval of     Dysport^®/Reloxin^®  for  cosmetic  <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">While <font color="blue">Beaufour Ipsen </font>    </font><font color="blue">previously</font>  licensed  Dysport^®/Reloxin^®  to  Inamed for the cosmetic     <font color="blue">indication</font> in the <font color="blue">United States</font>, it will regain its <font color="blue">licensed rights from</font>     Inamed in <font color="blue">connection</font> with our <font color="blue">acquisition</font> of Inamed</td>
    </tr>
    <tr>
      <td>It is our belief that     <font color="blue">Beaufour Ipsen </font><font color="blue"><font color="blue">will likely</font> relicense</font> its rights to a partner in the United     States,  which  license  could  include  other  <font color="blue">geographic regions</font> and     <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Beaufour Ipsen </font>has marketed Dysport^® in Europe since 1991,     prior to our European <font color="blue">commercialization</font> of Botox^® in 1992</td>
    </tr>
    <tr>
      <td>Also, <font color="blue">Mentor     </font>Corporation is <font color="blue">conducting <font color="blue"><font color="blue">clinical trial</font>s</font></font> for a competing <font color="blue">neuromodulator</font> in     the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In addition, we are aware of competing <font color="blue">neuromodulator</font>s     currently being developed and <font color="blue"><font color="blue">commercialize</font>d</font> in Asia, Europe, South America     and other markets</td>
    </tr>
    <tr>
      <td>A Chinese entity received approval to market a botulinum     toxin in China in 1997, and we believe that it has launched or is planning     to launch its <font color="blue">botulinum toxin</font> product in other <font color="blue">lightly regulated markets</font> in     Asia, South America and Central America</td>
    </tr>
    <tr>
      <td>These <font color="blue">lightly regulated markets</font> may     not require adherence to the FDA’s current Good Manufacturing Practice, or     cGMP, <font color="blue">regulations</font>, or the <font color="blue">regulatory</font> <font color="blue">requirements</font> of the European Medical     Evaluation Agency or other <font color="blue">regulatory</font> agencies in countries that are members     of the Organization for Economic Cooperation and Development</td>
    </tr>
    <tr>
      <td>Therefore,     companies operating in these <font color="blue">markets may</font> be able to produce <font color="blue">products at</font> a     <font color="blue">lower cost than</font> we can</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">Merz Pharmaceuticals </font>received approval     from German <font color="blue">authorities</font> for a <font color="blue">botulinum toxin</font> and launched its product in     July 2005, and a Korean company is conducting <font color="blue">Phase III </font><font color="blue"><font color="blue">clinical trial</font>s</font> for     a <font color="blue">botulinum toxin</font> in Korea</td>
    </tr>
    <tr>
      <td>This product received <font color="blue">exportation <font color="blue">approval from</font></font>     Korean <font color="blue">authorities</font> in early 2005</td>
    </tr>
    <tr>
      <td>Our sales of Botox^® could be <font color="blue">materially</font>     and  <font color="blue">negatively impacted by</font> this <font color="blue">competition</font> or <font color="blue">competition</font> from other     companies that might obtain FDA approval or <font color="blue">approval from</font> other <font color="blue">regulatory</font>     <font color="blue">authorities</font> to market a <font color="blue">neuromodulator</font></td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font>      If our <font color="blue">acquisition</font> <font color="blue">of Inamed </font>is consummated, our <font color="blue">principal <font color="blue">competitor</font></font>     in the <font color="blue"><font color="blue">United States</font> </font>for breast implants will be <font color="blue">Mentor Corporation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Mentor     </font>announced that it received an “approvable letter” from the FDA for its     silicone breast implants in July 2005</td>
    </tr>
    <tr>
      <td><font color="blue">If Mentor </font>receives approval to market     and <font color="blue">sell silicone breast implants</font> in the <font color="blue"><font color="blue">United States</font> </font>before we do, their     <font color="blue">silicone breast implants would</font> be the <font color="blue">only approved silicone breast implants</font>     in the <font color="blue">United States</font>, giving Mentor a <font color="blue">competitive</font> advantage over us in the     United  States  breast  implant market, at least in the short term</td>
    </tr>
    <tr>
      <td>In     addition, <font color="blue">Medicis Corporation </font><font color="blue">began marketing</font> Restylane^®, a dermal filler,     <font color="blue">in January </font>2004</td>
    </tr>
    <tr>
      <td>Through our purchase of Inamed, we will acquire Juvederm^®,     a non-animal, hyaluronic acid-based dermal filler</td>
    </tr>
    <tr>
      <td>Juvederm^® is not yet     <font color="blue">approved by</font> the FDA for sale in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Inamed began a clinical     study of Juvederm^® in the <font color="blue"><font color="blue">United States</font> </font>during in the <font color="blue">fourth quarter</font> of     2004 and completed the filing of a <font color="blue">premarket approval application with</font> the     <font color="blue">FDA in <font color="blue">December </font></font>2005</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that Inamed will receive approval     to market Juvederm^® in the <font color="blue">United States</font>, or if Juvederm^® is approved,     that Juvederm^® <font color="blue">will offer equivalent</font> or <font color="blue">greater facial aesthetic benefits</font>     to <font color="blue">competitive</font> dermal filler products, that it will be <font color="blue">competitive</font> in price     or <font color="blue">gain acceptance</font> in the marketplace</td>
    </tr>
    <tr>
      <td>We also face <font color="blue">competition</font> from generic drug <font color="blue">manufacture</font>rs in the United     States and <font color="blue"><font color="blue">international</font>ly</font></td>
    </tr>
    <tr>
      <td>For instance, Falcon Pharmaceuticals, Ltd, an     affiliate of Alcon Laboratories, Inc, is <font color="blue">currently attempting</font> to obtain FDA     approval  for  and to launch a <font color="blue">brimonidine product</font> to <font color="blue">compete with</font> our     Alphagan^®P product</td>
    </tr>
    <tr>
      <td>Changes in the <font color="blue">consumer marketplace</font> and <font color="blue">economic conditions</font> may <font color="blue">adversely</font>     <font color="blue">affect sales</font> or <font color="blue">product margins</font> of Botox^® or Botox^® Cosmetic</td>
    </tr>
    <tr>
      <td>Botox^® Cosmetic is a <font color="blue">consumer product</font></td>
    </tr>
    <tr>
      <td>If we fail to anticipate,     identify or to react to <font color="blue">competitive</font> products or if <font color="blue">consumer preferences</font> in     the  cosmetic  marketplace shift to other <font color="blue">treatments</font> for the temporary     <font color="blue">improvement</font> in the appearance of moderate to <font color="blue">severe glabellar lines</font>, we may     experience  a decline in demand for Botox^® Cosmetic</td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue">popular media</font> has at times in the past produced, and <font color="blue">may continue</font> in the     future to produce, negative reports and publicity regarding the efficacy,     safety or side effects of Botox^® Cosmetic</td>
    </tr>
    <tr>
      <td>Consumer <font color="blue">perceptions</font> of Botox^®     Cosmetic may be <font color="blue">negatively impacted by</font> these reports and for other reasons,     including the use of unapproved <font color="blue">botulinum toxin</font>s that result in injury,     which may cause demand to decline</td>
    </tr>
    <tr>
      <td>Demand for Botox^® Cosmetic may also be <font color="blue">materially</font> <font color="blue">adversely</font> affected     by changing <font color="blue">economic conditions</font></td>
    </tr>
    <tr>
      <td>Generally, the costs of cosmetic procedures     are borne by <font color="blue">individuals</font> without <font color="blue">reimbursement</font> from their medical insurance     providers or <font color="blue">government</font> programs</td>
    </tr>
    <tr>
      <td><font color="blue">Individuals </font>may be <font color="blue">less willing</font> to incur     the costs of these procedures in weak or uncertain economic <font color="blue">environment</font>s,     and demand for Botox^® Cosmetic could be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Changes in applicable tax laws may <font color="blue">adversely</font> <font color="blue">affect sales</font> or product     margins of Botox^® or Botox^® Cosmetic</td>
    </tr>
    <tr>
      <td>Because Botox^® and Botox^® Cosmetic     are <font color="blue"><font color="blue">pharmaceutical</font> products</font>, we <font color="blue">generally</font> do not collect or pay state sales     or other <font color="blue">tax on sales</font> of Botox^® or Botox^® Cosmetic</td>
    </tr>
    <tr>
      <td>We could be required     to collect and pay state sales or other tax <font color="blue">associated with</font> prior, current     or <font color="blue">future years on sales</font> of Botox^® or Botox^® Cosmetic</td>
    </tr>
    <tr>
      <td>In addition to any     <font color="blue">retroactive taxes</font> and <font color="blue">corresponding interest</font> and penalties that could be     assessed, if we were required to collect or pay state sales or other tax     <font color="blue"><font color="blue">associated with</font> current</font> or <font color="blue">future years on sales</font> of Botox^® or Botox^®     Cosmetic,  our sales of, or our <font color="blue">product margins</font> on, Botox^® or Botox^®     Cosmetic could be <font color="blue">adversely</font> affected due to the <font color="blue">increased cost associated</font>     with those products</td>
    </tr>
    <tr>
      <td>We could experience <font color="blue">difficulties</font> obtaining or creating the raw material     needed to produce our products and <font color="blue"><font color="blue">interruption</font>s</font> in the supply of raw     <font color="blue">materials could disrupt</font> our <font color="blue">manufacturing</font> and cause our sales and     <font color="blue">profitability</font> to decline</td>
    </tr>
    <tr>
      <td>The  loss  of  a  material  supplier or the <font color="blue">interruption</font> of our     <font color="blue">manufacturing</font> processes could <font color="blue">adversely</font> affect our ability to <font color="blue">manufacture</font> or     sell many of our products</td>
    </tr>
    <tr>
      <td>We obtain the <font color="blue">specialty chemicals</font> that are the     <font color="blue">active <font color="blue">pharmaceutical</font> ingredients</font> in certain of our <font color="blue">products from single</font>     sources, who must maintain <font color="blue">compliance with</font> the FDA’s cGMP <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>If we     experience <font color="blue">difficulties</font> acquiring <font color="blue">sufficient quantities</font> of these materials                                         18       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font>from  our  existing  suppliers,  or  if  our suppliers are found to be     non-compliant with the cGMPs, obtaining the required <font color="blue">regulatory</font> approvals,     including from the FDA, to use <font color="blue">alternative</font> suppliers may be a lengthy and     uncertain process</td>
    </tr>
    <tr>
      <td>A lengthy <font color="blue">interruption</font> of the supply of one or more of     these materials could <font color="blue">adversely</font> affect our ability to <font color="blue">manufacture</font> and supply     products, <font color="blue">which could</font> cause our sales and <font color="blue">profitability</font> to decline</td>
    </tr>
    <tr>
      <td>In     addition, the <font color="blue">manufacturing</font> process to create the raw material <font color="blue">necessary</font> to     produce Botox^® is <font color="blue">technically complex</font> and requires <font color="blue">significant</font> lead-time</td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">failure by</font> us</font> to <font color="blue">forecast demand</font> for, or to maintain an <font color="blue">adequate supply</font>     of, the raw material and finished product could result in an <font color="blue">interruption</font> in     the supply of Botox^® and a resulting decrease in sales of the product</td>
    </tr>
    <tr>
      <td>If we consummate the Inamed <font color="blue">acquisition</font>, we <font color="blue">will rely on</font> a single     supplier for <font color="blue">silicone raw materials used</font> in some of our products</td>
    </tr>
    <tr>
      <td>We will     also depend on third party <font color="blue">manufacture</font>rs for <font color="blue">silicone molded components</font> and     facial  aesthetics product lines, with the exclusion of the bovine and     human-based collagen products</td>
    </tr>
    <tr>
      <td>These third party <font color="blue">manufacture</font>rs must maintain     <font color="blue">compliance with</font> FDA’s Quality System Regulation, or QSR, <font color="blue">which sets forth</font>     the current good <font color="blue">manufacturing</font> practice <font color="blue">requirements</font> for <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>Any material reduction in our raw material supply or a <font color="blue">failure by</font> our third     party <font color="blue">manufacture</font>rs to maintain <font color="blue">compliance with</font> the QSR could result in     <font color="blue">decreased sales</font> of our products and a decease in our revenues</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future <font color="blue">success depends</font> upon</font> our ability to develop <font color="blue">new products</font>, and new     <font color="blue"><font color="blue">indication</font>s</font> for <font color="blue">existing products</font>, that achieve <font color="blue">regulatory</font> approval for     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>For our business model to be successful, we <font color="blue">must continually</font> develop,     test and <font color="blue">manufacture</font> <font color="blue">new products</font> or achieve new <font color="blue"><font color="blue">indication</font>s</font> for the use of     our <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>Prior to marketing, these <font color="blue">new products</font> and product     <font color="blue"><font color="blue">indication</font>s</font>  must  satisfy  stringent <font color="blue">regulatory</font> standards and receive     requisite approvals or <font color="blue">clearances</font> from <font color="blue">regulatory</font> <font color="blue">authorities</font> in the United     States and abroad</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font>, <font color="blue">regulatory</font> review and approval, and     <font color="blue">commercialization</font>  processes are time consuming, costly and subject to     <font color="blue">numerous factors</font> that may delay or prevent the <font color="blue">development</font>, approval or     clearance, and <font color="blue">commercialization</font> of <font color="blue">new products</font>, including <font color="blue">legal actions</font>     brought  by  our  <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>To obtain approval or clearance of new     <font color="blue"><font color="blue">indication</font>s</font> or products in the <font color="blue">United States</font>, we must submit, among other     information, the results of preclinical and <font color="blue">clinical studies</font> on the new     <font color="blue">indication</font> or <font color="blue">product candidate</font> <font color="blue">to the FDA </font>The number of preclinical and     <font color="blue">clinical studies</font> that will be required for FDA <font color="blue">approval varies depending on</font>     the new <font color="blue">indication</font> or <font color="blue">product candidate</font>, the disease or condition for which     the  new  <font color="blue">indication</font>  or  product  candidate is in <font color="blue">development</font> and the     <font color="blue">regulations</font> applicable to that new <font color="blue">indication</font> or <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>Even if     we believe that the data collected from <font color="blue"><font color="blue">clinical trial</font>s</font> of new <font color="blue"><font color="blue">indication</font>s</font>     for our <font color="blue">existing products</font> or for our <font color="blue">product candidate</font>s are promising, the     FDA <font color="blue">may find such data</font> to be insufficient to <font color="blue">support approval</font> of the new     <font color="blue">indication</font> or product</td>
    </tr>
    <tr>
      <td>The FDA can delay, limit or <font color="blue">deny approval</font> of a new     <font color="blue">indication</font> or <font color="blue">product candidate</font> for many reasons, including:         •  a <font color="blue">determination</font> that the new <font color="blue">indication</font> or <font color="blue">product candidate</font> is not     safe and <font color="blue">effective</font>;       •  the FDA may interpret our preclinical and <font color="blue">clinical data</font> in <font color="blue">different</font>     ways than we do;       •  the FDA may not approve our <font color="blue">manufacturing</font> processes or <font color="blue">facilities</font>;       •  the FDA may require us to perform post-marketing <font color="blue">clinical studies</font>; or       •  the FDA may change its <font color="blue">approval policies</font> or adopt new <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Products that we are currently developing, other <font color="blue">future product</font>     <font color="blue">candidates</font> or new <font color="blue"><font color="blue">indication</font>s</font> for our <font color="blue">existing products</font> may or may not     receive the <font color="blue">regulatory</font> approvals <font color="blue">necessary</font> for marketing or may receive such     <font color="blue">approvals only</font> after delay or <font color="blue"><font color="blue">unanticipated</font> costs</font></td>
    </tr>
    <tr>
      <td>Delays or <font color="blue">unanticipated</font>     costs  in  any  part  of the process or our <font color="blue">inability</font> to obtain timely     <font color="blue">regulatory</font> approval for our products, including those <font color="blue">attributable</font> to, among     other things, our failure to maintain <font color="blue">manufacturing</font> <font color="blue">facilities</font> in compliance     with all applicable <font color="blue">regulatory</font> <font color="blue">requirements</font>, including cGMPs and QSR, could     cause our operating results to suffer and our stock price to decrease</td>
    </tr>
    <tr>
      <td>We     are also required to pass pre-approval reviews and <font color="blue">plant inspections</font> of our     and our suppliers’ <font color="blue">facilities</font> to <font color="blue">demonstrate</font> our <font color="blue">compliance with</font> cGMPs and     QSR             Further, even if we receive FDA and other <font color="blue">regulatory</font> approvals for a     new <font color="blue">indication</font> or product, the <font color="blue">product may</font> later exhibit adverse effects     that limit or prevent its <font color="blue">widespread use</font> or that force us to withdraw the     <font color="blue">product from</font> the market or to revise our labeling to limit the <font color="blue"><font color="blue">indication</font>s</font>     for which the <font color="blue">product may</font> be prescribed</td>
    </tr>
    <tr>
      <td>In addition, even if we receive the     <font color="blue">necessary</font> <font color="blue">regulatory</font> approvals, we <font color="blue">cannot assure</font> you that new                                         19       _________________________________________________________________    [73]Table of <font color="blue">Contents       </font>products  or  <font color="blue"><font color="blue">indication</font>s</font>  will  achieve <font color="blue">market acceptance</font></td>
    </tr>
    <tr>
      <td>Our future     <font color="blue">performance will</font> be <font color="blue">affected by</font> the <font color="blue">market acceptance</font> of products such as     Lumigan^®, Alphagan^® P, Combigan^tm, Restasis^®, Acular LS^®, Zymar^®,     Botox^® and, if we consummate our <font color="blue">acquisition</font> <font color="blue">of Inamed </font>and, if <font color="blue">approved by</font>     the FDA, Juvederm^® and <font color="blue">breast implant products</font>, as well as FDA approval of     new <font color="blue"><font color="blue">indication</font>s</font> for Botox^®, and <font color="blue">new products</font> such as our Lumigan^®/timolol     <font color="blue">combination</font>, Posurdex^® and memantine</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that these or     any other compounds or products that we are developing for <font color="blue">commercialization</font>     will  be  <font color="blue">approved by</font> the FDA for marketing or that we will be able to     <font color="blue">commercialize</font> them on terms that will be profitable, or at all</td>
    </tr>
    <tr>
      <td>If any of     our <font color="blue">products cannot</font> be <font color="blue">successfully</font> or timely <font color="blue"><font color="blue">commercialize</font>d</font>, our operating     results could be <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Our product <font color="blue">development</font> efforts may not result in <font color="blue"><font color="blue">commercial product</font>s</font></td>
    </tr>
    <tr>
      <td>We intend to continue an <font color="blue">aggressive research</font> and <font color="blue">development</font> program</td>
    </tr>
    <tr>
      <td><font color="blue">Successful </font>product <font color="blue">development</font> in the <font color="blue"><font color="blue">pharmaceutical</font> industry</font> is highly     uncertain,  and  very  few research and <font color="blue">development</font> projects produce a     <font color="blue">commercial product</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">candidates</font> that appear promising in the early     phases of <font color="blue">development</font>, such as in early human <font color="blue"><font color="blue">clinical trial</font>s</font>, may fail to     reach the market for a number of reasons, such as:         •  the <font color="blue">product candidate</font> did not <font color="blue">demonstrate</font> acceptable <font color="blue">clinical trial</font>     results <font color="blue">even though</font> it <font color="blue">demonstrate</font>d positive pre<font color="blue">clinical trial</font> results;        •   the <font color="blue">product candidate</font> was not <font color="blue">effective</font> in treating a specified     condition or illness;       •  the <font color="blue">product candidate</font> had harmful side effects in humans or animals;       •  the <font color="blue">necessary</font> <font color="blue">regulatory</font> bodies, such as the FDA, did not approve the     <font color="blue">product candidate</font> for an <font color="blue">intended use</font>;       •  the <font color="blue">product candidate</font> was not economical for us to <font color="blue">manufacture</font> and     <font color="blue">commercialize</font>;       •  other companies or people have or may have <font color="blue"><font color="blue">proprietary</font> rights</font> to the     <font color="blue">product candidate</font>, such as patent rights, and will not <font color="blue">let us sell</font> it on     <font color="blue">reasonable terms</font>, or at all;        •  the <font color="blue">product candidate</font> is not cost <font color="blue">effective</font> in light of existing     <font color="blue">therapeutic</font>s; and       •  certain of our <font color="blue">licensors</font> or <font color="blue">partners may fail</font> to <font color="blue">effective</font>ly conduct     clinical <font color="blue">development</font> or clinical <font color="blue">manufacturing</font> activities</td>
    </tr>
    <tr>
      <td>Several of our <font color="blue">product candidate</font>s have failed or been <font color="blue">discontinued</font> at     various  stages in the product <font color="blue">development</font> process, including, but not     limited to, our <font color="blue">oral formulation</font> of tazarotene for the treatment of moderate     to very <font color="blue">severe psoriasis</font></td>
    </tr>
    <tr>
      <td>Of course, there may be other factors that prevent     <font color="blue">us from marketing</font> a product</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> we will be able to produce     <font color="blue">commercially</font>  <font color="blue">successful products</font></td>
    </tr>
    <tr>
      <td>Further, <font color="blue">clinical trial</font> results are     <font color="blue">frequently susceptible</font> to varying <font color="blue">interpretations</font> by scientists, medical     personnel, <font color="blue">regulatory</font> personnel, statisticians, and others, which may delay,     limit, or prevent further clinical <font color="blue">development</font> or <font color="blue">regulatory</font> approvals of a     <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>Also, the length of time that it takes for us to complete     <font color="blue"><font color="blue">clinical trial</font>s</font> and obtain <font color="blue">regulatory</font> approval for product marketing has in     the past varied by product and by the <font color="blue">intended use</font> of a product</td>
    </tr>
    <tr>
      <td>We expect     that this <font color="blue">will likely</font> be the case with future <font color="blue">product candidate</font>s and we     <font color="blue">cannot predict</font> the length of time to complete <font color="blue">necessary</font> <font color="blue"><font color="blue">clinical trial</font>s</font> and     obtain <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>If we are unable to obtain and maintain <font color="blue">adequate protection</font> for our     <font color="blue"><font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> <font color="blue">associated with</font></font> the <font color="blue"><font color="blue">technologies</font> incorporated</font>     into our products, our business and results of <font color="blue"><font color="blue">operations</font> could suffer</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part on our ability to obtain patents or rights     to patents, protect trade secrets and other <font color="blue"><font color="blue">proprietary</font> <font color="blue">technologies</font></font> and     processes, operate <font color="blue">without infringing upon</font> the <font color="blue"><font color="blue">proprietary</font> rights</font> of others,     and <font color="blue">prevent others from infringing on</font> our patents, <font color="blue">trademarks</font>, service marks     and other <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font></td>
    </tr>
    <tr>
      <td>Upon the expiration or loss of     <font color="blue">patent protection</font> for a product, we can lose a <font color="blue">significant</font> portion of sales     of  that  product  in  a  very short period of time as other companies     <font color="blue">manufacture</font> generic forms of our <font color="blue">previously</font> protected product at lower cost,     without having had to incur <font color="blue">significant</font> research and <font color="blue">development</font> costs in     <font color="blue">formulating</font> the product</td>
    </tr>
    <tr>
      <td>Therefore, our <font color="blue">future financial success may depend</font>     in part on obtaining <font color="blue">patent protection</font> for <font color="blue"><font color="blue">technologies</font> incorporated</font> into     our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">such patents will</font> be issued, or that     any existing or <font color="blue">future patents will</font> be of <font color="blue">commercial benefit</font></td>
    </tr>
    <tr>
      <td>In addition,     it is impossible to anticipate the breadth or degree of protection that any     <font color="blue">such patents will</font> afford, and we <font color="blue">cannot assure</font> you that                                         20       _________________________________________________________________    [74]Table of <font color="blue">Contents       </font>any <font color="blue">such patents will</font> not be <font color="blue">successfully</font> challenged in the future</td>
    </tr>
    <tr>
      <td>If we     are <font color="blue">unsuccessful</font> in obtaining or preserving <font color="blue">patent protection</font>, or if any of     our products rely on unpatented <font color="blue">proprietary</font> technology, we <font color="blue">cannot assure</font> you     that <font color="blue">others will</font> not <font color="blue">commercialize</font> products substantially identical to those     products</td>
    </tr>
    <tr>
      <td>Generic drug <font color="blue">manufacture</font>rs are <font color="blue">currently challenging</font> the patents     <font color="blue">covering certain</font> of our products and we expect that they <font color="blue">will continue</font> to do     so in the future</td>
    </tr>
    <tr>
      <td>We believe that the protection of our <font color="blue">trademarks</font> and service marks is     an important factor in <font color="blue">product recognition</font> and in our ability to maintain or     <font color="blue">increase market</font> share</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">adequately protect</font> our rights in our     various <font color="blue">trademarks</font> and service marks <font color="blue">from <font color="blue">infringement</font></font>, their value to us     could be lost or diminished</td>
    </tr>
    <tr>
      <td>If the marks we use are found to infringe upon     the trademark or service mark of another company, we could be forced to stop     using those marks and, as a result, we <font color="blue">could lose</font> the value of those marks     and could be liable for damages caused by an <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>In addition to     <font color="blue"><font color="blue">intellectual</font> property</font> protections afforded to <font color="blue">trademarks</font>, service marks and     <font color="blue">proprietary</font> know-how by the <font color="blue">various countries</font> in which our <font color="blue">proprietary</font>     products are sold, we seek to protect our <font color="blue">trademarks</font>, service marks and     <font color="blue">proprietary</font> know-how through confidentiality agreements with <font color="blue">third parties</font>,     including our partners, customers, employees and <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>It is possible     that these <font color="blue">agreements will</font> be breached or that they will not be enforceable     in <font color="blue">every instance</font>, and that we will not have <font color="blue">adequate remedies</font> for any such     breach</td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that our <font color="blue">trade secrets will become known</font> or     <font color="blue">independently</font> developed by our <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>Third parties may challenge, invalidate, or <font color="blue">circumvent</font> our patents and     patent  <font color="blue">applications</font>  relating to our products, <font color="blue">product candidate</font>s and     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Challenges </font>may result in potentially <font color="blue">significant</font> harm to our     business</td>
    </tr>
    <tr>
      <td>The cost of responding to these <font color="blue">challenges</font> and the <font color="blue">inherent costs</font>     to  defend  the  validity of our patents, including the <font color="blue">prosecution</font> of     <font color="blue">infringement</font>s and the related litigation, could be substantial and can     preclude or delay <font color="blue">commercialization</font> of products</td>
    </tr>
    <tr>
      <td>Such <font color="blue">litigation also could</font>     require a substantial <font color="blue">commitment</font> of our <font color="blue">management</font>’s time</td>
    </tr>
    <tr>
      <td>For certain of     our <font color="blue">product candidate</font>s, <font color="blue">third parties</font> may have patents or <font color="blue">pending patents</font>     that they claim prevent us from commercializing certain <font color="blue">product candidate</font>s     in <font color="blue">certain territories</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part on our ability to obtain     and <font color="blue">defend patent rights</font> and other <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> that are     important to the <font color="blue">commercialization</font> of our products and <font color="blue">product candidate</font>s</td>
    </tr>
    <tr>
      <td>For <font color="blue">additional</font> information on our material patents see “Patents, Trademarks     and Licenses” in Item 1 of Part I of this report, “Business</td>
    </tr>
    <tr>
      <td>”       <font color="blue">Importation </font>of products from Canada and other <font color="blue">countries into</font> the United     States may lower the prices we receive for our products</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, some of our products are subject to <font color="blue">competition</font>     <font color="blue">from <font color="blue">lower priced versions</font></font> of our products and <font color="blue">competing products from</font>     Canada, Mexico and other countries where <font color="blue">government</font> price controls or other     market  dynamics  result  in <font color="blue">lower prices</font></td>
    </tr>
    <tr>
      <td>Our products that require a     <font color="blue">prescription</font> in the <font color="blue"><font color="blue">United States</font> </font>are <font color="blue">often available</font> to consumers in these     <font color="blue">markets without</font> a <font color="blue">prescription</font>, which may cause consumers to <font color="blue">further seek</font>     out our products in these <font color="blue">lower priced markets</font></td>
    </tr>
    <tr>
      <td>The ability of patients and     other customers to obtain these <font color="blue">lower priced imports</font> has grown <font color="blue">significant</font>ly     as  a result of the Internet, an expansion of pharmacies in Canada and     elsewhere  targeted <font color="blue">to American </font>purchasers, the increase in US-based     <font color="blue">businesses</font>  <font color="blue">affiliated</font>  with <font color="blue">Canadian </font><font color="blue">pharmacies marketing</font> <font color="blue">to American </font>    purchasers, and other factors</td>
    </tr>
    <tr>
      <td>These foreign imports are <font color="blue">illegal under</font>     current  US law,  with  the  <font color="blue">sole exception</font> of limited quantities of     <font color="blue">prescription</font> drugs imported for <font color="blue">personal use</font></td>
    </tr>
    <tr>
      <td>However, the volume of imports     continues to rise due to the limited <font color="blue">enforcement resources</font> of the FDA and     the US Customs Service, and there is increased political pressure to     permit the imports as a mechanism for expanding access to lower priced     medicines</td>
    </tr>
    <tr>
      <td><font color="blue">In <font color="blue">December </font></font>2003, <font color="blue">Congress </font>enacted the Medicare Prescription Drug,     Improvement, and Modernization Act of 2003</td>
    </tr>
    <tr>
      <td>This <font color="blue">law contains provisions</font>     that may change US <font color="blue">import laws</font> and expand consumers’ ability to import     <font color="blue">lower priced versions</font> of our products and <font color="blue">competing products from</font> Canada,     where there are <font color="blue">government</font> price controls</td>
    </tr>
    <tr>
      <td>These changes to US <font color="blue">import laws</font>     will not take effect unless and until the <font color="blue">Secretary </font>of Health and Human     Services certifies that the changes will lead to substantial savings for     consumers and will not create a <font color="blue">public health safety issue</font></td>
    </tr>
    <tr>
      <td>The former     <font color="blue"><font color="blue">Secretary </font>of Health and Human Services </font>did not make such a <font color="blue">certification</font></td>
    </tr>
    <tr>
      <td>However, it is possible that the current <font color="blue">Secretary </font>or a subsequent <font color="blue">Secretary </font>    could make the <font color="blue">certification</font> in the future</td>
    </tr>
    <tr>
      <td>As <font color="blue">directed by</font> Congress, a task     force on drug <font color="blue">importation</font>                                         21       _________________________________________________________________    [75]Table of <font color="blue">Contents       </font><font color="blue">recently conducted</font> a <font color="blue">comprehensive study</font> regarding the <font color="blue">circumstances under</font>     which drug <font color="blue">importation</font> could be <font color="blue">safely conducted</font> and the <font color="blue">consequences</font> of     <font color="blue">importation</font> on the health, medical costs and <font color="blue">development</font> of <font color="blue">new medicines</font>     for US consumers</td>
    </tr>
    <tr>
      <td>The <font color="blue">task force issued</font> its report in <font color="blue">December </font>2004,     finding that there are <font color="blue">significant</font> safety and <font color="blue">economic issues</font> that must be     addressed before <font color="blue">importation</font> of <font color="blue">prescription</font> drugs is permitted, and the     current <font color="blue">Secretary </font>has not yet announced any plans to make the required     <font color="blue">certification</font></td>
    </tr>
    <tr>
      <td>In addition, federal <font color="blue">legislative</font> proposals have been made to     implement the changes to the US <font color="blue">import laws</font> without any <font color="blue">certification</font>, and     to <font color="blue">broaden permissible imports</font> in other ways</td>
    </tr>
    <tr>
      <td>Even if the changes to the     US <font color="blue">import laws</font> do not take effect, and other changes are not enacted,     <font color="blue">imports from</font> Canada and elsewhere <font color="blue">may continue</font> to increase due to market and     political forces, and the limited <font color="blue">enforcement resources</font> of the FDA, the     <font color="blue">US Customs Service </font>and other <font color="blue">government</font> agencies</td>
    </tr>
    <tr>
      <td>For example, state and     local <font color="blue">government</font>s have suggested that they <font color="blue">may import drugs from</font> Canada for     employees covered by state health plans or others, and some already have     implemented such plans</td>
    </tr>
    <tr>
      <td>The  <font color="blue">importation</font>  of  foreign  products  <font color="blue">adversely</font>  affects our     <font color="blue">profitability</font>  in  the  United  States</td>
    </tr>
    <tr>
      <td>This <font color="blue">impact could</font> become more     <font color="blue">significant</font> in the future, and the <font color="blue">impact could</font> be <font color="blue">even greater</font> if there is     a further change in the law or if state or local <font color="blue">government</font>s take further     steps to <font color="blue">import products from abroad</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">will continue</font> to expose us to risks of <font color="blue">environment</font>al     <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>Our product <font color="blue">development</font> programs and <font color="blue">manufacturing</font> processes involve     the <font color="blue">controlled use</font> of hazardous materials, chemicals and <font color="blue">toxic compounds</font></td>
    </tr>
    <tr>
      <td>These  programs  and  processes  expose us to risks that an <font color="blue"><font color="blue">accident</font>al</font>     <font color="blue">contamination</font>  could  lead  to  non<font color="blue">compliance with</font> <font color="blue">environment</font>al laws,     <font color="blue">regulatory</font> enforcement actions and claims for <font color="blue">personal injury</font> and property     damage</td>
    </tr>
    <tr>
      <td>If an <font color="blue">accident</font> occurs, or if we discover <font color="blue">contamination</font> caused by     prior <font color="blue">operations</font>, including by prior owners and operators of properties we     acquire, we could be liable for cleanup <font color="blue">obligations</font>, damages and fines</td>
    </tr>
    <tr>
      <td>The     substantial <font color="blue">unexpected costs</font> we <font color="blue">may incur could</font> have a <font color="blue">significant</font> and     adverse effect on our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may experience losses due to <font color="blue">product liability</font> claims, <font color="blue">product recalls</font> or     <font color="blue">corrections</font></td>
    </tr>
    <tr>
      <td>The design, <font color="blue">development</font>, <font color="blue">manufacture</font> and sale of our <font color="blue">products involve</font>     an <font color="blue">inherent risk</font> of <font color="blue">product liability</font> or other claims <font color="blue">by consumers</font> and other     <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We have in the past been, and continue to be, subject to     various <font color="blue">product liability</font> claims and lawsuits</td>
    </tr>
    <tr>
      <td>In addition, we have in the     past and may in the <font color="blue">future recall</font> or issue field <font color="blue">corrections</font> related to our     <font color="blue">products due</font> to <font color="blue">manufacturing</font> deficiencies, labeling errors or other safety     or <font color="blue">regulatory</font> reasons</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will not in the future     experience  material losses due to <font color="blue">product liability</font> claims, lawsuits,     <font color="blue">product recalls</font> or <font color="blue">corrections</font></td>
    </tr>
    <tr>
      <td>If we consummate our <font color="blue">acquisition</font> of Inamed, we will assume Inamed’s     product  <font color="blue">liability risks</font></td>
    </tr>
    <tr>
      <td>Inamed has in the past and continues to be a     <font color="blue">manufacture</font>r of <font color="blue">breast implant products</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> and sale of breast     <font color="blue">implant products entails risk</font> of <font color="blue">product liability</font> claims</td>
    </tr>
    <tr>
      <td>Historically,     other breast implant <font color="blue">manufacture</font>rs that suffered such claims in the 1990’s     were forced to cease <font color="blue">operations</font> or even to declare <font color="blue">bankruptcy</font></td>
    </tr>
    <tr>
      <td>Additionally,     Inamed is seeking to <font color="blue">reintroduce silicone breast implants</font> in the United     States</td>
    </tr>
    <tr>
      <td>If it obtains FDA approval to <font color="blue">market silicone breast implants</font> for     breast augmentation, such approval may come with <font color="blue">significant</font> restrictions     and <font color="blue">requirements</font>, including the need for a patient registry, follow up     MRI’s, and substantial <font color="blue">Phase IV </font><font color="blue">clinical trial</font> <font color="blue">commitment</font>s</td>
    </tr>
    <tr>
      <td>We also face a     substantial risk of <font color="blue">product liability</font> claims from our <font color="blue">current eye care</font>,     <font color="blue">neuromodulator</font> and <font color="blue">skin care products</font> and, upon our <font color="blue">acquisition</font> of Inamed,     may face similar <font color="blue">risks <font color="blue">associated with</font></font> Inamed’s <font color="blue">obesity intervention</font> and     <font color="blue">facial aesthetics products</font></td>
    </tr>
    <tr>
      <td>Additionally, our <font color="blue">pharmaceutical</font> and <font color="blue">aesthetic products may</font> cause, or     may appear to cause, <font color="blue">serious adverse</font> side effects or <font color="blue">potentially dangerous</font>     <font color="blue">drug interactions</font> if misused or <font color="blue">improperly prescribed</font></td>
    </tr>
    <tr>
      <td>We are subject to     <font color="blue">adverse event</font> reporting <font color="blue">regulations</font> that require us to report <font color="blue">to the FDA </font>or     similar bodies in other countries if our products are <font color="blue">associated with</font> a     death or <font color="blue">serious injury</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">adverse event</font>s, among others, could result in     <font color="blue">additional</font>  <font color="blue">regulatory</font>  controls,  such  as  the performance of costly     post-approval <font color="blue">clinical studies</font> or revisions to our approved labeling, which     <font color="blue">could limit</font> the <font color="blue"><font color="blue">indication</font>s</font> or <font color="blue">patient population</font> for our products or could     even lead to the withdrawal of a <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>Furthermore, any     adverse publicity <font color="blue">associated with</font> such an event could cause consumers to     seek <font color="blue">alternative</font>s to our products, which may cause                                         22       _________________________________________________________________    [76]Table of <font color="blue">Contents       </font>our sales to decline, even if our products are ultimately determined not to     have been the primary cause of the event</td>
    </tr>
    <tr>
      <td>Negative <font color="blue">publicity concerning</font> the safety of our <font color="blue">products may harm</font> our sales     and we may be forced to <font color="blue">withdraw products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font>and potential and existing patients may have a number of     concerns about the safety of our products, including Botox^®, eye care     <font color="blue">pharmaceutical</font>s, <font color="blue">skin care products</font>, and, if we consummate our <font color="blue">acquisition</font>     of Inamed, breast implants, <font color="blue">obesity intervention</font> products and <font color="blue">facial dermal</font>     fillers, whether or not <font color="blue">such concerns</font> have a basis in <font color="blue">generally</font> accepted     science or peer-reviewed scientific research</td>
    </tr>
    <tr>
      <td>Negative publicity — whether     accurate or inaccurate — about our products, based on, for example, news     about  Botox^®, <font color="blue">breast implant litigation</font> or <font color="blue">regulatory</font> activities and     <font color="blue">development</font>s,  <font color="blue">whether involving us</font> or a <font color="blue">competitor</font>, or new <font color="blue">government</font>     regulation, could <font color="blue">materially</font> reduce <font color="blue">market acceptance</font> of our products and     could result in <font color="blue">product withdrawals</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">significant</font> negative     <font color="blue">publicity could</font> result in an increased number of <font color="blue">product liability</font> claims,     whether or not these claims have a basis in scientific fact</td>
    </tr>
    <tr>
      <td>Furthermore,     any adverse publicity <font color="blue">associated with</font> such an event could cause consumers to     seek <font color="blue">alternative</font>s to our products, which may cause our sales to decline,     even if our products are ultimately determined not to have been the primary     cause of the event</td>
    </tr>
    <tr>
      <td>Health <font color="blue">care initiatives</font> and other cost-containment pressures could cause us     to sell our <font color="blue">products at</font> <font color="blue">lower prices</font>, resulting in <font color="blue">decreased revenues</font></td>
    </tr>
    <tr>
      <td>Some of our products are purchased or reimbursed by state and federal     <font color="blue">government</font> <font color="blue">authorities</font>, private health insurers and other <font color="blue">organizations</font>,     such  as  health  maintenance <font color="blue">organizations</font>, or HMOs, and managed care     <font color="blue">organizations</font>,  or  MCOs</td>
    </tr>
    <tr>
      <td>Third  party  <font color="blue">payors increasingly challenge</font>     <font color="blue">pharmaceutical</font> product pricing</td>
    </tr>
    <tr>
      <td>The <font color="blue">trend toward managed healthcare</font> in the     United  States, the growth of <font color="blue">organizations</font> such as HMOs and MCOs, and     various  <font color="blue">legislative</font> proposals and <font color="blue">enactments</font> to reform healthcare and     <font color="blue">government</font> insurance programs, including the Medicare Prescription Drug,     Improvement, and Modernization Act of 2003, or MMA, could <font color="blue">significant</font>ly     influence the manner in which <font color="blue"><font color="blue">pharmaceutical</font> products</font> are prescribed and     purchased, <font color="blue">which could</font> result in <font color="blue">lower prices</font> and/or a reduction in demand     for  our  products</td>
    </tr>
    <tr>
      <td>For  example,  <font color="blue">effective</font> January 1, 2006, the MMA     established  a new Medicare outpatient <font color="blue">prescription</font> drug benefit under     <font color="blue">Part D The MMA </font><font color="blue">also established</font> a <font color="blue">competitive</font> <font color="blue">acquisition</font> program, or CAP,     in which physicians who <font color="blue">administer</font> drugs in their offices will be offered an     option to acquire drugs covered under <font color="blue">the Medicare Part B </font><font color="blue">benefit from</font>     vendors who are selected in a <font color="blue">competitive</font> bidding process</td>
    </tr>
    <tr>
      <td>Winning vendors     have <font color="blue">been selected based on criteria</font> that include their bid price</td>
    </tr>
    <tr>
      <td>Such cost     <font color="blue">containment measures</font> and healthcare reforms could <font color="blue">adversely</font> affect our     ability to sell our products</td>
    </tr>
    <tr>
      <td>Under a new rule, <font color="blue">implementation</font> <font color="blue">of the CAP     </font>will begin in July 2006</td>
    </tr>
    <tr>
      <td>Furthermore, individual states have <font color="blue">become increasingly aggressive</font> in     passing  <font color="blue">legislation</font>  and implementing <font color="blue">regulations</font> designed to control     <font color="blue">pharmaceutical</font> product pricing, including price or patient <font color="blue">reimbursement</font>     constraints, discounts, <font color="blue">restrictions on</font> certain product access, <font color="blue">importation</font>     from other countries and <font color="blue">bulk purchasing</font></td>
    </tr>
    <tr>
      <td>Legally <font color="blue">mandated price controls on</font>     <font color="blue">payment amounts by third party payors</font> or other <font color="blue">restrictions could negatively</font>     and <font color="blue">materially</font> impact our revenues and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We encounter     similar <font color="blue">regulatory</font> and <font color="blue">legislative</font> issues in <font color="blue">most countries outside</font> the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We expect there <font color="blue">will continue</font> to be federal and state laws and/or     <font color="blue">regulations</font>, proposed and implemented, that <font color="blue">could limit</font> the amounts that     <font color="blue">international</font>,  federal and state <font color="blue">government</font>s will pay for <font color="blue">health care</font>     products  and  services</td>
    </tr>
    <tr>
      <td>The  extent  to  which future <font color="blue">legislation</font> or     <font color="blue">regulations</font>, if any, relating to the <font color="blue">health care</font> industry or third-party     coverage and <font color="blue">reimbursement</font> may be enacted or what effect such <font color="blue">legislation</font> or     <font color="blue">regulation would</font> have on our business <font color="blue">remains uncertain</font></td>
    </tr>
    <tr>
      <td>Such measures or     other <font color="blue">health care</font> system reforms that are <font color="blue">adopted could</font> have a material     adverse effect on our ability to <font color="blue">commercialize</font> <font color="blue">successfully</font> our products or     <font color="blue">could limit</font> or eliminate our spending on <font color="blue">development</font> projects and affect our     ultimate <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In addition, regional healthcare <font color="blue">authorities</font> and individual hospitals     are <font color="blue">increasingly using bidding procedures</font> to determine what <font color="blue">pharmaceutical</font>     products and <font color="blue">which suppliers will</font> be included in their                                         23       _________________________________________________________________    [77]Table of <font color="blue">Contents       </font><font color="blue">prescription</font> drug and other <font color="blue">healthcare programs</font></td>
    </tr>
    <tr>
      <td>This can <font color="blue">reduce demand</font> for     our products or <font color="blue">put pressure on</font> our product pricing, <font color="blue">which could</font> negatively     affect our revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We are subject to risks arising from currency exchange rates, <font color="blue">which could</font>     increase our costs and may cause our <font color="blue">profitability</font> to decline</td>
    </tr>
    <tr>
      <td>We collect and pay a substantial portion of our sales and <font color="blue">expenditures</font>     in currencies other than the US dollar</td>
    </tr>
    <tr>
      <td>Therefore, <font color="blue">fluctuations</font> in foreign     <font color="blue">currency exchange rates affect</font> our operating results</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that future exchange rate movements, inflation or other related <font color="blue">factors will</font>     not have a material adverse effect on our sales, gross profit or operating     expenses</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">risks <font color="blue">associated with</font></font> doing business <font color="blue"><font color="blue">international</font>ly</font></td>
    </tr>
    <tr>
      <td>Our business is subject to <font color="blue">certain risks inherent</font> in <font color="blue">international</font>     business, many of which are beyond our control</td>
    </tr>
    <tr>
      <td>These risks include, among     other things:         •  adverse changes in tariff and <font color="blue">trade protection measures</font>;       •  unexpected changes in foreign <font color="blue">regulatory</font> <font color="blue">requirements</font>, including     <font color="blue">quality standards</font> and other <font color="blue">certification</font> <font color="blue">requirements</font>;       •  potentially negative <font color="blue">consequences</font> from changes in or <font color="blue">interpretations</font> of     tax laws;       •  differing labor <font color="blue">regulations</font>;       •  changing <font color="blue">economic conditions</font> in countries where our products are sold     or <font color="blue">manufacture</font>d or in other countries;       •  <font color="blue">differing local product preferences</font> and product <font color="blue">requirements</font>;       •  <font color="blue">exchange rate risks</font>;       •  <font color="blue">restrictions on</font> the <font color="blue">repatriation</font> of funds;       •  <font color="blue">political unrest</font> and <font color="blue">hostilities</font>;       •  <font color="blue">differing degrees</font> of protection for <font color="blue"><font color="blue">intellectual</font> property</font>; and       •  <font color="blue">difficulties</font> in <font color="blue">coordinating</font> and managing foreign <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any of these factors, or any other <font color="blue">international</font> factors, could have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we can <font color="blue">successfully</font> manage these risks     or avoid their effects</td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue"><font color="blue">intellectual</font> property</font> litigation and <font color="blue">infringement</font>     claims, <font color="blue">which could</font> cause us to incur <font color="blue">significant</font> expenses and losses or     <font color="blue">prevent us from selling</font> our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our <font color="blue">products will</font> not <font color="blue">infringe patents</font> or     other <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> held by <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In the event we     discover that we may be infringing third party patents or other <font color="blue">intellectual</font>     <font color="blue">property rights</font>, we may not be able to obtain <font color="blue">licenses from</font> those third     parties on <font color="blue">commercially</font> attractive terms or at all</td>
    </tr>
    <tr>
      <td>We may have to defend,     and have recently defended, against charges that we <font color="blue">violated patents</font> or the     <font color="blue">proprietary</font>   rights  of  third  parties</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation  </font>is  costly  and     time-consuming, and diverts the attention of our <font color="blue">management</font> and technical     personnel</td>
    </tr>
    <tr>
      <td>In addition, if we infringe the <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> of     others, we <font color="blue">could lose</font> our right to develop, <font color="blue">manufacture</font> or <font color="blue">sell products</font> or     could  be  required  to  pay  <font color="blue">monetary damages</font> or royalties to license     <font color="blue">proprietary</font>  rights  from <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>An adverse <font color="blue">determination</font> in a     judicial or <font color="blue">administrative proceeding</font> or a failure to obtain <font color="blue">necessary</font>     licenses could prevent us from <font color="blue">manufacturing</font> or selling our products, which     could  harm  our  business, <font color="blue">financial condition</font>, prospects, results of</td>
    </tr>
  </tbody>
</table>